» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-AALL0932

Trial

Clinical Trial Title

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Trial Status

Closed to Enrollment

Start Date

August 17, 2010

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Acute Lymphoblastic Leukemia (ALL) Standard Risk B-Precursor

Description

This partially randomized phase III trial studies different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.

Eligibility Criteria

Patients must be enrolled on COG AALL08B1 (Classification Study) prior to enrollment on COG AALL0932

Age: >365 days and <10 years of age

Must have an initial white blood cell count <50,000/uL

Newly diagnosed Standard Risk B-precursor ALL

Patients with Down syndrome are also eligible

Patients must have not received any prior cytotoxic chemotherapy for the current diagnosis of ALL or any cancer diagnosed previously, with the exception of steroids and intrathecal cytarabine for the current diagnosis of ALL

Patients with CNS3 status are not eligible for this study; are eligible for COG High Risk AALL1131 Study

Patients with testicular leukemia are not eligible for this study

Notes

https://clinicaltrials.gov/ct2/show/NCT01190930

Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:08 AM